Actemra 162 mg/0.9 mL ACTPen® autoinjector Images
Generic Name: tocilizumab
This medication has been identified as Actemra 162 mg/0.9 mL ACTPen® autoinjector. It is supplied by Genentech, Inc.
Actemra is used in the treatment of Giant Cell Arteritis; Rheumatoid Arthritis; COVID-19; Cytokine Release Syndrome; Polyarticular Juvenile Idiopathic Arthritis and belongs to the drug class interleukin inhibitors. Risk cannot be ruled out during pregnancy. Actemra 162 mg/0.9 mL ACTPen® autoinjector is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Actemra
- Generic Name
- tocilizumab
- Strength
- 162 mg/0.9 mL ACTPen® autoinjector
- Availability
- Prescription only
- Drug Class
- Interleukin inhibitors
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Genentech, Inc.
- National Drug Code (NDC)
- 50242-0143
More about Actemra (tocilizumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (49)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Support group
- FDA approval history
- Drug class: interleukin inhibitors
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.